Application of alisol B in preparation of nasopharyngeal carcinoma resisting medicine

The invention relates to application of alisol B in preparation of an anti-nasopharyngeal carcinoma medicine, belongs to the field of medicines, and discloses application of a monomeric compound alisol B extracted from rhizoma alismatis in preparation of the anti-nasopharyngeal carcinoma medicine. The alisol B can effectively inhibit nasopharyngeal carcinoma cell proliferation, the inhibition effect is enhanced along with the increase of drug action time and drug concentration, and the western blot result shows that the alisol B can down-regulate Akt and PI3K protein expression levels. Alisol B is one of the main chemical components of rhizoma alismatis, and has great development and application values and market prospects in preparation of nasopharynx cancer resistant drugs. 本发明涉及泽泻醇B在抗鼻咽癌药物制备中的应用，属于医药领域，本发明公开一种从泽泻中提取的一种单体化合物泽泻醇B在抗鼻咽癌药物制备中的应用。泽泻醇B能有效地抑制鼻咽癌细胞增殖，并且抑制效果随着药物作用时间与药物浓度的提高而增强，蛋白免疫印迹结果显示，泽泻醇B可下调Akt和PI3K蛋白表达水平。泽泻醇B是泽泻的主要化学成分之一，其在抗鼻咽癌药物制备方面具有较大的开发应用价值和市场前景。